Iovance Biotherapeutics

Iovance Biotherapeutics

Yahoo Finance • 2 days ago

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

An updated edition of the July 8, 2026, article. The global oncology market is undergoing significant transformation, driven by the rising burden of cancer, aging populations and rapid advances in medical science. According to the America... Full story

Yahoo Finance • 5 days ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 16 days ago

Iovance (IOVA) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Senior Vice President, Investor Relations and Corporate Communications - Sara Pellegrino Interim CEO and President - Frederick Vogt Chief Fina... Full story

Yahoo Finance • 23 days ago

Why Investors Are Watching These Healthcare Movers

DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (https://247mnn.com/) – ClearOne (NASDAQ: CLRO), NeOnc Technologies (NASDAQ: NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in today’s roundup.... Full story

Yahoo Finance • 23 days ago

Iovance surges as Amtagvi powers Q2 beat

[Green arrow pointing up and a dollar sign] Iovance Biotherapeutics (IOVA [https://seekingalpha.com/symbol/IOVA]) climbed more than 40% to reach a new 52-week high on Thursday after the company kept its revenue outlook under review follow... Full story

Yahoo Finance • last month

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltratin... Full story

Yahoo Finance • last month

Top Biotech Gainers: APLM Climbs 22%; IOVA, RCEL On Watch; MANE Gains On Hair Loss Data

(RTTNews) - Today's biotech movers include Apollomics following its return to Nasdaq compliance, Iovance and AVITA ahead of Q2 earnings updates, Annexon, awaiting topline data in dry age-related macular degeneration with geographic atrophy... Full story

Yahoo Finance • 2 months ago

This Stock Is Up 74% This Year: Is It Too Late to Buy?

Key Points Iovance Biotherapeutics is making strong regulatory and commercial progress with its key product. However, it faces several risks that could send the stock plummeting. 10 stocks we like better than Iovance Biotherapeutics › Af... Full story

Yahoo Finance • 2 months ago

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Healthcare is changing through AI and personalized cell therapy. Which of these high-growth innovators represents the better risk-adjusted opportunity for your portfolio today as you evaluate Heartflow Inc. (NASDAQ:HTFL) and Iovance Biothe... Full story

Yahoo Finance • 2 months ago

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Key Points Amgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income. Iovance Biotherapeutics offers high growth potential through its innovative cell therapies for advanced cancers. Should inve... Full story

Yahoo Finance • 3 months ago

Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is among the hidden penny stocks to invest in. As of June 10, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was trading near the low levels reported on June 3, before the stock appreciated followin... Full story

Yahoo Finance • 3 months ago

Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the top penny stocks to buy in investors’ stock portfolio. On June 1, research firm Citizens reiterated a Market Outperform rating on Iovanace Biotherapeutics (NASDAQ:IOVA) with a $5 pr... Full story

Yahoo Finance • 3 months ago

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc... Full story

Yahoo Finance • 3 months ago

FDA Clears IND For Iovance's IOV-5001 In Treating Cancer; Phase 1/2 Enrollment Planned For H2 2026

(RTTNews) - Iovance Biotherapeutics Inc. (IOVA), a commercial-stage biopharmaceutical company, on Monday announced FDA clearance of the investigational new drug (IND) submission for IOV-5001, a tumor-infiltrating lymphocyte (TIL) therapy.... Full story

Yahoo Finance • 3 months ago

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focus... Full story

Yahoo Finance • 3 months ago

Iovance Biotherapeutics to Present at Upcoming Conference

SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies f... Full story

Yahoo Finance • 4 months ago

Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy Now?

Is VKTX a good stock to buy? We came across a bullish thesis on Viking Therapeutics, Inc. on Charlie Evans’s Substack by Charlie Evans PhD. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.'s share was... Full story

Yahoo Finance • 4 months ago

Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi Drug

Iovance Biotherapeutics Inc (NASDAQ:IOVA) is among the must-buy penny stocks to invest in now. The stock has climbed more than 66% over the past six months and currently trades at around $3.86. On April 10, Jefferies reaffirmed a Buy ratin... Full story

Yahoo Finance • 5 months ago

Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster

Neurocrine Biosciences logo 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking Neurocrine Biosciences (NASDAQ:NBIX) detailed its planned acquisition of Soleno Therapeutics on a conference call Monday, outlining the deal terms, the s... Full story

Yahoo Finance • 6 months ago

Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine

Tempus AI, Inc. (NASDAQ:TEM) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. On March 3, the company announced a strategic partnership with Merck to fast-track the development of AI-driven precision medicine and suppo... Full story